AI-driven smart workflow solutions provider Aikenist has successfully raised a seed round of funding led by Venture Catalysts, with participation from prominent investors including MARL Fund, Quant Fund, C-CAMP, Nandak Growth Catalysts, and several angel investors. Although the funding amount was not disclosed, the involvement of these investors signals significant backing for Aikenist’s growth and innovation in the healthcare industry.
Founded by Ashwin Amarapur, Aikenist is revolutionizing the medical imaging landscape by offering AI-accelerated magnetic resonance imaging (MRI) technology for diagnostic centres and hospitals. The company’s core mission is to enhance MRI efficiency, enabling faster scans, improved diagnostic capabilities, and more rapid delivery of results. This advancement is particularly aimed at expanding access to critical imaging for conditions like cancer, Alzheimer’s disease, and musculoskeletal (MSK) disorders.
Aikenist’s SaaS-based business model, which offers both annual subscription plans and pay-per-use options, provides flexible solutions to healthcare providers of all sizes, from small clinics to large hospital networks.
At the heart of Aikenist’s innovation is its flagship product, QuickSuite, which streamlines radiology processes from scan acquisition to reporting. QuickSuite includes three key components:
- QuickRad: an AI-powered PACS & RIS system.
- QuickScan: a patented solution for faster MRI scanning.
- QuickDiag: specialized suites for disease detection and quantification.
With this funding, Aikenist is poised to scale its operations and further its goal of making high-quality, AI-enhanced medical imaging accessible to a broader population, driving the early detection and management of critical illnesses.
